Why IMU is a multi multi bagger, page-26268

I certainly have no criticism of those unhappy with the current shareprice, it is very disappointing.
However those saying the science is no good and those leveling criticism of what management are paid just don't seem to examine the facts.
Leslie Chong as CEO is paid a good wage but it is by no means excessive, she has taken shares in lieu of cash as a way of reducing the impact on the bottom line, many of the others have done the same.
They have taken risks as much as many of us investors have, as they could have earned very good money elsewhere.
It is too early to sày if the programs that IMU are running will have great success or turn out to be not good enough to take their place on the market as SOC treatment for many types of cancer.
It has been mentioned by Yuman Fong and others that these trials have been going at lightning speed, and yet that is still not good enough for some on this site.
Plenty of shareholders in the Biotechnology space can tell you of 10-15 even 20 years of drug development and battling approval processes, IMU trials have only been going for 4-5 years and some are in phase II trials where many are picked up or licensed out.
Azer-cel is due to go into a registrational trial if current results bear fruit in larger numbers of patients, this trial began last year!
Criticism is OK to be levelled at those not doing their job, but if you are not part of the organisation how would you know whether someone is meeting their KPI's.
There are plenty of other opportunities out there in the sharemarket if you don't feel you are getting fair return for your income, move on and stop trying to save others from the fate you have experienced, life is too short for this waste of time.

DYOR opinion only